Medcap Limited - Accounts to registrar (filleted) - small 22.3

Medcap Limited - Accounts to registrar (filleted) - small 22.3


IRIS Accounts Production v22.4.0.132 11823171 Board of Directors 1.7.21 30.6.22 30.6.22 0 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure118231712021-06-30118231712022-06-30118231712021-07-012022-06-30118231712020-02-29118231712020-03-012021-06-30118231712021-06-3011823171ns16:EnglandWales2021-07-012022-06-3011823171ns15:PoundSterling2021-07-012022-06-3011823171ns11:Director12021-07-012022-06-3011823171ns11:PrivateLimitedCompanyLtd2021-07-012022-06-3011823171ns11:SmallEntities2021-07-012022-06-3011823171ns11:AuditExempt-NoAccountantsReport2021-07-012022-06-3011823171ns11:SmallCompaniesRegimeForDirectorsReport2021-07-012022-06-3011823171ns11:SmallCompaniesRegimeForAccounts2021-07-012022-06-3011823171ns11:FullAccounts2021-07-012022-06-301182317112021-07-012022-06-3011823171ns11:EntityHasNeverTraded2021-07-012022-06-3011823171ns11:Director22021-07-012022-06-3011823171ns11:RegisteredOffice2021-07-012022-06-3011823171ns6:CurrentFinancialInstruments2022-06-3011823171ns6:CurrentFinancialInstruments2021-06-3011823171ns6:ShareCapital2022-06-3011823171ns6:ShareCapital2021-06-3011823171ns6:SharePremium2022-06-3011823171ns6:SharePremium2021-06-3011823171ns6:RetainedEarningsAccumulatedLosses2022-06-3011823171ns6:RetainedEarningsAccumulatedLosses2021-06-3011823171ns6:IntangibleAssetsOtherThanGoodwill2021-07-012022-06-3011823171ns6:PatentsTrademarksLicencesConcessionsSimilar2021-07-012022-06-3011823171ns6:DevelopmentCostsCapitalisedDevelopmentExpenditure2021-07-012022-06-3011823171ns6:PlantMachinery2021-07-012022-06-3011823171ns6:PatentsTrademarksLicencesConcessionsSimilar2021-06-3011823171ns6:DevelopmentCostsCapitalisedDevelopmentExpenditure2021-06-3011823171ns6:PatentsTrademarksLicencesConcessionsSimilar2022-06-3011823171ns6:DevelopmentCostsCapitalisedDevelopmentExpenditure2022-06-3011823171ns6:PatentsTrademarksLicencesConcessionsSimilar2021-06-3011823171ns6:DevelopmentCostsCapitalisedDevelopmentExpenditure2021-06-3011823171ns6:PlantMachinery2021-06-3011823171ns6:PlantMachinery2022-06-3011823171ns6:PlantMachinery2021-06-3011823171ns6:WithinOneYearns6:CurrentFinancialInstruments2022-06-3011823171ns6:WithinOneYearns6:CurrentFinancialInstruments2021-06-3011823171ns6:RetainedEarningsAccumulatedLosses2021-06-3011823171ns6:SharePremium2021-06-3011823171ns6:RetainedEarningsAccumulatedLosses2021-07-012022-06-30
REGISTERED NUMBER: 11823171 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2022

FOR

MEDCAP LIMITED

MEDCAP LIMITED (REGISTERED NUMBER: 11823171)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2022




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


MEDCAP LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 30 JUNE 2022







DIRECTORS: N W Young
M J Stocker-Harris





REGISTERED OFFICE: Create Business Hub
Ground Floor
5 Rayleigh Road
Shenfield
Essex
CM13 1AB





REGISTERED NUMBER: 11823171 (England and Wales)





ACCOUNTANTS: Tish Press & Company
Create Business Hub
Ground Floor
5 Rayleigh Road
Shenfield
Essex
CM13 1AB

MEDCAP LIMITED (REGISTERED NUMBER: 11823171)

BALANCE SHEET
30 JUNE 2022

2022 2021
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 559,512 559,512
Tangible assets 5 440,000 440,000
999,512 999,512

CURRENT ASSETS
Debtors 6 326,684 344,573
Cash at bank and in hand 1 1
326,685 344,574
CREDITORS
Amounts falling due within one year 7 349,558 355,302
NET CURRENT LIABILITIES (22,873 ) (10,728 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

976,639

988,784

CAPITAL AND RESERVES
Called up share capital 126 125
Share premium 8 999,975 999,975
Retained earnings 8 (23,462 ) (11,316 )
SHAREHOLDERS' FUNDS 976,639 988,784

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 June 2022.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2022 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 30 March 2023 and were signed on its behalf by:



N W Young - Director


MEDCAP LIMITED (REGISTERED NUMBER: 11823171)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2022

1. STATUTORY INFORMATION

Medcap Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences are being amortised evenly over their estimated useful life of nil years.

Development costs are being amortised evenly over their estimated useful life of nil years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery - 25% on cost

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2021 - NIL ) .

MEDCAP LIMITED (REGISTERED NUMBER: 11823171)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 JUNE 2022

4. INTANGIBLE FIXED ASSETS
Patents
and Development
licences costs Totals
£    £    £   
COST
At 1 July 2021
and 30 June 2022 25,339 534,173 559,512
NET BOOK VALUE
At 30 June 2022 25,339 534,173 559,512
At 30 June 2021 25,339 534,173 559,512

5. TANGIBLE FIXED ASSETS
Plant and
machinery
£   
COST
At 1 July 2021
and 30 June 2022 440,000
NET BOOK VALUE
At 30 June 2022 440,000
At 30 June 2021 440,000

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2022 2021
£    £   
Amounts owed by participating interests 326,534 343,061
VAT 150 1,512
326,684 344,573

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2022 2021
£    £   
Trade creditors 305,158 312,402
Amounts owed to participating interests 39,900 39,900
Accrued expenses 4,500 3,000
349,558 355,302

8. RESERVES
Retained Share
earnings premium Totals
£    £    £   

At 1 July 2021 (11,316 ) 999,975 988,659
Deficit for the year (12,146 ) (12,146 )
At 30 June 2022 (23,462 ) 999,975 976,513